Sun BioPharma, Inc. (SNBP) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 43 transactions totaling $1.1M, demonstrating a bearish sentiment with -$974.7K in net insider flow. The most recent transaction on Sep 10, 2020 involved a purchase of 1,000 shares valued at $2.7K.
No significant insider buying has been recorded for SNBP in the recent period.
No significant insider selling has been recorded for SNBP in the recent period.
Based on recent SEC filings, insider sentiment for SNBP is bearish with an Insider Alignment Score of 6/100 and a net flow of -$974.7K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Sun BioPharma, Inc. (SNBP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading SNBP stock, having executed 43 transactions in the past 90 days. The most active insider is Ryan Randall Gilbertson (Executive), who has made 7 transactions totaling $2.1M.
Get notified when executives and directors at SNBP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 10, 2020 | K. Simpson Jennifer | Executive | Purchase | 1,000 | $2.74 | $2.7K | |
| Sep 8, 2020 | W. Schaffer Paul | Executive | Purchase | 225 | $2.55 | $574 | |
| Sep 4, 2020 | W. Schaffer Paul | Executive | Purchase | 24,775 | $2.51 | $62.2K | |
| Sep 1, 2020 | T. Cullen Michael | Executive | Purchase | 10,000 | $N/A | $0 | |
| Sep 1, 2020 | K. Simpson Jennifer | Executive | Purchase | 2,424 | $N/A | $0 | |
| Sep 1, 2020 | Fratamico Arthur | Executive | Purchase | 2,424 | $N/A | $0 | |
| Sep 1, 2020 | Horvath Susan | Executive | Purchase | 2,424 | $N/A | $0 | |
| Jun 5, 2020 | Horvath Susan | Executive | Purchase | 2,500 | $N/A | $0 | |
| Jun 5, 2020 | W. Schaffer Paul | Executive | Purchase | 10,000 | $N/A | $0 | |
| May 22, 2020 | T. Cullen Michael | Executive | Purchase | 10,000 | $N/A | $0 | |
| May 22, 2020 | T. Cullen Michael | Executive | Purchase | 10,000 | $N/A | $0 | |
| Sep 20, 2019 | Gagnon Suzanne | Executive | Purchase | 7,142 | $N/A | $0 | |
| Sep 20, 2019 | W. Schaffer Paul | Executive | Purchase | 30,000 | $N/A | $0 | |
| Aug 30, 2019 | T. Cullen Michael | Executive | Purchase | 30,000 | $N/A | $0 | |
| Aug 30, 2019 | Horvath Susan | Executive | Purchase | 1,428 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 5 | $1.0M | 48.6% |
Award(A) | 2 | $735.0K | 34.3% |
Exercise(M) | 1 | $150.4K | 7.0% |
Payment(F) | 1 | $150.0K | 7.0% |
Purchase(P) | 26 | $65.5K | 3.1% |
Conversion(C) | 5 | $0 | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Insider selling pressure at Sun BioPharma, Inc. has increased, with 13 insiders executing 43 transactions across all time. Total sales of $1.0M significantly outpace purchases of $65.5K, resulting in a net outflow of $974.7K. This selling activity appears largely discretionary, which may warrant closer attention from investors.